We lead next-generation drug delivery platforms based on advanced technologies and devices.
Long-Acting Injectable
Platform Technology
Depot technology is a long-acting injectable platform designed to enable the sustained and controlled release of drugs over an extended period. As a next-generation formulation, it simplifies dosing regimens, improves patient adherence, and ultimately enhances therapeutic outcomes.
01
Reduced Medication Burden for Patients and Caregivers
Eliminates the need for daily dosing, reducing the medication burden for both patients and caregivers.
02
Stable Plasma Drug Concentrations
Controlled release kinetics maintain consistent plasma drug levels over time.
03
Reduced Side Effects from Rapid Concentration Changes
Minimizes side effects associated with abrupt fluctuations in drug concentration.
04
Improved Adherence Through Sustained Therapeutic Effects
Ensures continuous therapeutic efficacy, supporting long-term treatment adherence.
Focus areas
Hormonal Disorders
Applied to sex hormone therapies via systemic circulation, enabling stable therapeutic effects with monthly or quarterly dosing intervals
Precocious puberty
Prostate cancer
Metabolic Disorders
Improvement of low bioavailability (BA) of peptide drugs and patient adherence
Obesity
Growth hormone
CNS Disorders
Application to psychiatric and cognitive disorders utilizing the olfactory nerve and lymphatic system pathways
Depression
Schizophrenia
Hormonal Disorders
Applied to sex hormone therapies via systemic circulation, enabling stable therapeutic effects with monthly or quarterly dosing intervals
Precocious puberty
Prostate cancer
Metabolic Disorders
Improvement of low bioavailability (BA) of peptide drugs and patient adherence
Obesity
Growth hormone
CNS Disorders
Application to psychiatric and cognitive disorders utilizing the olfactory nerve and lymphatic system pathways
Depression
Schizophrenia
Core Competency
Defining new paradigms in treatment through advanced technology and differentiated research
Core Competency 01
CURE® Technology
Controlled Ultra-precision Release & Effect-optimized Microsphere
Next-Generation Long-Acting Microsphere Platform:
Ultra-precise release control, optimized therapeutic effects, and scalable manufacturing flexibility
Daewoong Pharmaceutical’s CURE® (Controlled Ultra-precision Release & Effect-Optimized Microsphere) technology is a next-generation drug delivery platform engineered not only to deliver drugs, but to achieve optimal therapeutic outcomes for patients.
By overcoming conventional technical limitations, CURE® precisely controls drug release and maximizes efficacy, setting a new standard for long-acting injectable formulations.
More than a conventional microsphere technology, CURE® represents an advanced platform designed to enhance patient quality of life and redefine the future of drug delivery.
- 1.
Controlled Ultra-precision
ReleasePrecisely controlled drug release
CURE® enables the precise design and modulation of drug release profiles, allowing drugs to be released at a consistent and predictable rate in the body. This minimizes initial burst release-related side effects while ensuring stable and sustained therapeutic efficacy.
- 2.
Effect Optimized
Optimized therapeutic performance
The engineered microspheres optimize drug concentration and duration of action to maximize therapeutic effectiveness. This allows for enhanced efficacy even at lower doses while significantly improving patient adherence.
- 3.
Ready to Scale
Ready to Scale - Scalable and flexible manufacturing
CURE® offers a highly flexible and scalable production system, enabling seamless transition from small-scale clinical sample production to large-scale commercial manufacturing. This ensures consistent product quality across all stages of development while maintaining operational efficiency.
Sustained‑Release Injectable Platform with Controlled Initial Release and Enhanced Bioavailability
FDA‑approved biodegradable polymers
- Hydrophobic amino acids
Patented hydrophobic amino acid surface modification technology
- Hydrophobic ion pairing (HIPA)
Hydrophobic Ion Pairing Agent acting on the surface of microspheres
Core Competency 02
End-to-End Process & Manufacturing Capabilities from Research to Commercialization
The value of CURE® lies in its ability to consistently reproduce precisely engineered drug release profiles—from early-stage research to full-scale commercial production.
Daewoong Pharmaceutical has established integrated process capabilities and infrastructure that enable:
- Advanced process design for precise control of microsphere-based release profiles
- Robust process parameter management systems ensuring batch-to-batch reproducibility
- Scalable strategies that directly translate lab-scale outcomes to commercial manufacturing, supported by analytical validation capabilities
These capabilities are realized through a fully integrated internal workflow—from microsphere fabrication and solvent removal to particle size control and release characterization—where each step is optimized to maintain the core performance of long-acting delivery systems.
Microsphere Emulsion Technology
A core manufacturing technology that forms O/W or W/O/W emulsions using active pharmaceutical ingredients and biodegradable polymers, followed by solvent removal and solidification to produce long-acting microsphere formulations.
- Enables effective suppression of initial burst release and stable release profile design based on proprietary formulation strategies (including excipient optimization)
- Allows precise control of particle size distribution through inlet nozzle-based process configuration
- Ensures high process reproducibility with minimized batch-to-batch variability through accumulated process expertise
- Provides scalability to maintain formulation characteristics from R&D to commercial production
Microsphere Spray drying Technology
A process in which a solution of active ingredients and polymers is atomized and rapidly dried to produce sustained-release microspheres.
- Enables consistent control of particle size and physicochemical properties through precise adjustment of spray and drying conditions
- Offers process safety and regulatory advantages by eliminating the use of organic solvents
- Ensures reproducibility and minimizes batch variability through a simplified, continuous manufacturing process
- Improves safety, suspendability, and injectability through efficient residual solvent removal
Multi-Process Manufacturing Platform
Daewoong systematically evaluates and optimizes a wide range of formulation compositions and process conditions at the research stage, identifying and accumulating key process parameters that influence long-acting release performance. This data-driven approach enhances understanding of formulation behavior and serves as the foundation for consistent technology transfer into development and manufacturing stages.
Inlet nozzle In-line mixer
Spray Dryer
Bead Mill
cGMP-Grade Dedicated Manufacturing Facility for Depot Injectables
- Dedicated cGMP-compliant manufacturing facility for depot injectables
- First-in-Korea implementation of Dual Chamber Syringe (DCS) filling system
- Annual production capacity of 600,000 prefilled syringes
- Fully integrated organization across R&D, QA, QC, and manufacturing
The manufacturing process is designed to ensure stable control of critical parameters that determine microsphere release characteristics, regardless of production scale—enabling consistent translation of R&D performance into commercial production.
Core Competency 03
Dedicated Injection Device Development & In-House Automated Filling Infrastructure to Enhance Dosing Convenience
These technologies and manufacturing capabilities do not remain limited to drug delivery performance, but are ultimately integrated into a Dual Chamber Syringe (DCS) system that also reflects usability at the actual point of administration.
The DCS is a dedicated injection device designed based on the physical characteristics and injection behavior of microsphere formulations, ensuring both stable injection performance and user convenience during administration.
DCS (Dual Chamber Syringe)
Injection Device
Automated DCS
Filling Infrastructure
- In-House Capability for Dedicated DCS Design and Development Based on Microsphere Formulation Characteristics
Daewoong possesses in-house capabilities to design and develop dedicated DCS injection devices that take into account microsphere formulation characteristics—such as particle size distribution, dispersion stability, and injection resistance—thereby achieving both stable injection behavior and user convenience simultaneously during administration.
- Patented DCS Container Design
Daewoong holds patents for DCS container structures designed to maintain formulation stability while also ensuring usability during handling and administration, thereby securing differentiated device competitiveness.
- Automated DCS Filling Process and Infrastructure
By applying automated filling processes optimized for DCS device characteristics, Daewoong improves filling precision and enables minimization of batch-to-batch variability.